Interpace Biosciences (OTCMKTS:IDXG) Issues Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) released its earnings results on Monday. The business services provider reported $0.01 EPS for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

Interpace Biosciences Price Performance

Interpace Biosciences stock traded up $0.09 during mid-day trading on Monday, reaching $1.70. The stock had a trading volume of 13,703 shares, compared to its average volume of 6,838. The company has a market capitalization of $7.53 million, a price-to-earnings ratio of -34.00 and a beta of 0.61. The company has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.77. Interpace Biosciences has a one year low of $0.77 and a one year high of $2.40.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.